Zhiyuan Zhou1, Xin Li1, Changying Chen2, Zhenchang Sun1, Jianguo Wen3, Mingzhi Zhang1
E-mail: realyuan1986@163. com
Abstract: Extranodal NK/T-cell Lymphoma (ENKL) are uncommon hematological malignancies with an aggressive clinical course and poor prognosis. Conventional anthracycline containing regimens demonstrate an unsatisfactory outcome. The frequent expression of the multidrug resistance (MDR) gene (P-glycoprotein) in NK lymphoma cells contributes to the refractoriness and dismal prognosis. We performed this meta-analysis to evaluate the efficacy and safety of L-asparaginase-based chemotherapy regimens in the treatment of advanced, relapsed or refractory ENKL. Electronic databases, including the PubMed database, Cochrane Library, EMBA, SE, were searched for clinical trials involving L-asparaginase-based regimens for ENKL. Fixed-effects analysis demonstrated the summary CR (complete remission) rates was 52% (95% CI=42% to 61%), summary OR (overall remission) rates was 78% (95% CI = 70% to 86%). With respect to main adverse events, the incidence rates of leukopenia, liver dysfunction and anaphylactic reactions were 60. 0%, 50. 8%, 11. 4%, respectively. In conclusion, L-asparaginase-based chemotherapy regimens present remarkable efficacy in the treatment for advanced, relapsed or refractory ENKL, while the incidence of adverse events is high.
[Zhiyuan Zhou, Xin Li, Changying Chen, Zhenchang Sun, Jianguo Wen, Mingzhi Zhang. L-asparaginase-Based Chemotherapy Regimens for Advanced, Relapsed or Refractory Extranodal NK/T-cell Lymphoma:A Systematic Review and Meta-Analysis. Life Sci J 2013:10(1):3150-3154]. (ISSN: 1097-8135). http://www. lifesciencesite. com.
Key Words: extranodal NK/T-cell lymphoma;L-Asparaginase;systematic review; Meta-Analysis. 3